MANUFACTURING AND TECHNOLOGY DEVELOPMENT master AGREEMENT July 2nd, 2020 Between Orchard Therapeutics (Europe) Limited and MolMed S.p.A.Manufacturing and Technology Development Master Agreement • August 6th, 2020 • Orchard Therapeutics PLC • Biological products, (no disgnostic substances)
THIS MANUFACTURING AND TECHNOLOGY DEVELOPMENT MASTER AGREEMENT (the “Agreement”) is entered into and made effective as of July 2nd, 2020 (the “Effective Date”)
CERTAIN CONFIDENTIAL INFORMATION MARKED BY [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.Manufacturing and Technology Development Master Agreement • March 14th, 2023 • Orchard Therapeutics PLC • Biological products, (no disgnostic substances)
This amendment is effective as of the date the last signature is made ("Effective Date") between Orchard Therapeutics (Europe) Limited, with registered offices 245 Hammersmith Road, 3rd Floor, London, W6 8PW, United Kingdom England, company number 09759506, (OTL) and AGC Biologics S.p.A. with registered offices at via Meucci 3, Bresso (MI) Italy (AGC)
